Localization of the bronchodilator effect induced by type A natriuretic peptide in asthmatic subjects.
Type A natriuretic peptide (CDD/ANP-99-126) in its circulating form was analyzed with respect to the localization of its bronchodilating effects in asthmatic subjects in vivo. The intravenous infusion of 5.7, 11.4, and 17.1 pmol kg-1 min-1 CDD/ANP-99-126 caused a significant bronchodilation of both central and peripheral airways. While the localization of the bronchodilating effects was similar to beta 2-agonists, an improvement in lung function parameters comparable to these substances was not observed. But other members of the natriuretic peptide family may reveal a stronger bronchodilating potency.
Flüge
T
T
Abteilung Pneumologie, Medizinische Hochschule Hannover, Germany.
Fabel
H
H
Wagner
T O
TO
Forssmann
W G
WG
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000503:physiopathology*; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects; D001993:Bronchodilator Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000494:pharmacology*
D001993:Bronchodilator Agents; D010446:Peptide Fragments; D009320:Atrial Natriuretic Factor